ASSOCIATION BETWEEN HIGH-RISK DISEASE LOCI AND RESPONSE TO ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR WET AGE-RELATED MACULAR DEGENERATION | Zendy

Anton Orlin | Zendy; Dexter Hadley | Zendy; Woohyok Chang | Zendy; Allen C. Ho | Zendy; Gary C. Brown | Zendy; Richard Kaiser | Zendy; Carl D. Regillo | Zendy; Ashlee N. Godshalk | Zendy; Audun Lier | Zendy; Brian Kaderli | Zendy; Dwight Stambolian | Zendy

Open Access

ASSOCIATION BETWEEN HIGH-RISK DISEASE LOCI AND RESPONSE TO ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR WET AGE-RELATED MACULAR DEGENERATION

Author(s) -

Anton Orlin,

Dexter Hadley,

Woohyok Chang,

Allen C. Ho,

Gary C. Brown,

Richard Kaiser,

Carl D. Regillo,

Ashlee N. Godshalk,

Audun Lier,

Brian Kaderli,

Dwight Stambolian

Publication year - 2011

Publication title -

retina

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.24

H-Index - 120

eISSN - 1539-2864

pISSN - 0275-004X

DOI - 10.1097/iae.0b013e31822a2c7c

Subject(s) - ranibizumab , macular degeneration , medicine , bevacizumab , visual acuity , vascular endothelial growth factor , cohort , retrospective cohort study , ophthalmology , single nucleotide polymorphism , genotype , gastroenterology , oncology , chemotherapy , vegf receptors , gene , biology , genetics

To investigate whether there is an association between known age-related macular degeneration genetic risk variants in the CFH, ARMS2, and HTRA1 genes and response to anti-vascular endothelial growth factor (VEGF) (ranibizumab or bevacizumab) treatment for wet age-related macular degeneration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research